One October night seven years ago, Lin Fukun walked into the laboratory as usual. Soon, the whole laboratory was boiling.

While examining an image of a DNA section, they finally found the EPO (erythropoietin) gene sequence that they had been searching for and studying for years.

History, too, changed from that moment.

After a short celebration, Lin and his team were even more nervous about R&D and continued to explore the path of turning EPO into a drug.

Six years later, on June 1, 1989, Epogen, developed by Lin Fukun's team on the basis of EPO, passed the FDA approval and was successfully marketed.

Epogen is primarily used to treat anemia caused by chronic renal failure and is Amgen's first successful product. At the time of its birth, Amgen, which had been established for nearly 10 years, was on the verge of bankruptcy due to long-term R&D investment, but no successful product sales.

But Lin and Epogen changed all that.

On Epogen's IPO day, Amgen's revenue reached $20 million, and the company's stock price soared, and many people became millionaires and billionaires overnight. A year later, the company's revenue exceeded $130 million.

A small company on the verge of bankruptcy also saved its life and barely survived the most difficult year.

But this life, without a sustained harvest, only lasted for a year, and now it has fallen into a precarious situation.

Lin Fukun's team and two teams led by Dr. George Lassman, one of the company's founders, jointly tackled the difficulty of a new drug, and it had been going well. But in the end, in the last clinical trial, because the side effects kept appearing, it was trapped in the repeated review of the FDA, and it could not be passed.

There is no way to market new drugs.

Amgen has invested $230 million over six years to research this new drug. It looks like it's about to reap the fruits, but now it's likely to fall halfway to success.

As a brilliant scientist of Chinese descent, Lin Fukun, like George Lasman, is a scientist of the purest kind.

Let the two of them lead their teams to be stuffy in the laboratory, and it can be dozens of days, or even months. But if they want to figure out how to run the company and how to attract investment, these two excellent biomedical scientists really can't do it.

For the space of the company.

These two company's research bosses are anxious in their eyes, but they can't imagine another way to help the company get out of the predicament, except to speed up the research and development process of new drugs.

The problem is that the research of new drugs requires a lot of funding. Without funding, there would be no experimental materials, no use of experimental equipment, and no salaries for scientific research assistants.

Then there is no way to continue the experiment.

Scientific experiments are the least time-intensive and most expensive investment, often investing a lot of time, money and ability, and in the end there may be nothing.

Now the two doctors are sure that Amgen Pharma's new drug developed this time is on the right path, but there are some forks in the way, and after some time, they and their team will definitely be able to bring this medicine to the company, which can not only save patients, but also make the company's new drug.

The problem is that in the past few days, when they joined forces to go to Mr. President CEO to ask for funds, they could only get Mr. Pentax's helpless wry smile and the persuasion of letting them be quiet for a while.

The two PhDs were eager for new funding, but they also knew the dilemma of the CEO, Mr. Binder. During this period of time, Mr. President has been sleeping hard for the company to continue to receive investment, and the dark circles under his eyes are more terrible than anyone in the company.

The doctors didn't dare to blame Mr. President, they only hoped that God or Buddha would bless them, and that they could send an investor to give the company new investment funds and new funds to their team, so that they could research this new medicine and save the company from fire and water.

But I waited for more than a month.

There is still no good news, these two really pure doctors are thinking about going back to sell their villas or their own cars to support their research.

Wait until the end of March.

Finally got a good news from Mr. President, there are new investors.

But along with this good news, there was a request from investors who made the two doctors a little surprised, puzzled and even angry.

Dr. Lin Fukun, director of Amgen's Biologics Research Office, frowned and stood behind the company's chairman and founder, Dr. George Lasman, with an unhappy expression.

Because the new investor asked him to sign a VAM contract with Amgen Pharmaceutical, he would invest money to invest in Amgen Pharmaceutical, but in order to avoid his own money being wasted, he wanted to come into the R&D work of Amgen Pharmaceutical, help Amgen Pharmaceutical, find out the problem of excessive side effects of the new drug within a week, and then solve this problem, so that the new drug can be launched normally.

Joke!

He certainly disagreed.

It's so unbelievable!

This investor, although he is a medical genius who invented sildenafil. But sildenafil is a chemical medicine, and the difference between chemical medicine and biomedicine is much greater than that between the galaxy and the Mississippi River!

The other party's Ph.D. in Harvard Medicine, which is also a chemical pharmaceutical preparation, cannot be said to have no effect on a biomedical company like Amgen Pharmaceutical, but the effect will definitely not exceed that of the aunt sweeping the floor at the door of the laboratory!

What does he want to do in the lab?

Waste of time!

If the other party wants to interfere, then the biological reagents prepared before will be wasted!

Although he is an investor, he is the boss. But for the members of Amgen's R&D department, who are accustomed to frugality, it is a shame to waste!

Unfortunately, the pressure from the chairman and CEO is not something he can resist. In particular, the CEO also promised that the other party would invest more than $100 million at one time, and Amgen Pharma could burn money for at least another year......

Lin Fukun's attitude was not so resolute.

After a while, a Cadillac and a Mercedes-Benz C-Class stopped in front of everyone.

The number plate of the Mercedes-Benz C-class, Lin Fukun knows. It was Mr. President, who had worked hard for the company for several more years. And Cadillac, Lin Fukun doesn't know. But it should be the young man who published a few papers and thought he was the best in the world after studying sildenafil.

Scientific research is not so simple, don't think that the occasional discovery and creation makes scientific research as simple as a dinner party!!

Scientific research is serious!

Hum!!

I'm going to see the joke today!!

Lin Fukun thought in his heart.